secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-08-14T20:16:35+00:00
Accession:  0001104659-26-097180
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q2 2026 net loss $3.9M, cash down to $0.2M; advances NurOwn Phase 3b
-------------------------------------------------------------------------------

- Q2 2026 net loss $3.9M vs $2.9M in Q2 2025; EPS -$0.35 vs -$0.34.
- Cash, equivalents, restricted cash $0.2M at June 30, 2026, down from $1.03M a year earlier.
- G&A jumped to $2.7M from $1.5M; R&D was ~$1.0M vs $1.1M.
- Phase 3b ENDURANCE trial of NurOwn in ALS planned for ~200 patients under FDA SPA; Peter Pitts named Executive Chairman.
- Raised $400k in May 2026 private placement; H1 2026 total capital ~$2.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/0001104659-26-097180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-097180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer